Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, asks if health care providers are ready for this post pandemic world following the declaration of the end of the global health emergency from WHO in May 2023.

Accelerating bivalent booster vaccine campaigns for children could reduce pediatric hospitalizations and school absenteeism.

The US Department of Education, US Department of Health and Human Services, and the Biden-Harris Administration look to increase access to school-based health services, including mental health services, amid the national crisis. 

A new analysis found differences in the gut bacteria seen in adults with obesity, suggesting that changes in the gut microbiota that predispose to adult obesity may begin in early childhood.

Up to 95% of youth aged 13 to 17 years reported using a social media platform and more than a third said they use social media, “almost constantly,” according to a new advisory from the Surgeon General.

The Make-A-Wish program is not just for children with terminal illnesses, and pediatric HCPs play an important role in the process. Here's what you should know.

Finafta Anesthetic/Analgesic Liquid, containing 60% ethyl alcohol and 5% benzocaine has been found in the G-Supress DX Pediatric Cough Drops packaging, according to the FDA.

The newly FDA-approved prescription product delivers nalmefene to the nasal cavity to reverse the effects of opioid overdose.

Patients using adalimumab-adbm for chronic inflammatory disease treatment such as juvenile idiopathic arthritis (JIA), Crohn’s disease, and others, will have an autoinjector option beginning July 1, 2023, according to Boehringer Ingelheim.

Trends in the incidence of eye injuries associated with non-powder guns should be interpreted with caution as COVID-19 may have interfered with epidemiological trends.

Following the FDA approval of beremagene geperpavec (B-VEC) (Vyjuvek; Krystal Biotech) to treat dystrophic epidermolysis bullosa (DEB) patients aged 6 months and older, Bernard A. Cohen, MD, discusses its safety and efficacy and how it can change the treatment landscape for DEB.

The FDA has approved Krystal Biotech's beremagene geperpavec (B-VEC) (Vyjuvek; Krystal Biotech) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients aged 6 months and older. B-VEC is the first FDA-approved gene therapy treatment for DEB, according to the agency. In this Contemporary Pediatrics interview, Raj Chovatiya, MD, PhD, breaks down this much-anticipated FDA approval.

On May 11, 2023, the COVID-19 public health emergency ended. So…now what?

The FDA Advisory Committee recently voted in support of approval for Pfizer's maternal immunization vaccine to help prevent RSV in infants. In this Contemporary Pediatrics® interview, Tina Tan, MD, FAAP, FIDSA, FPIDS, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital, Chicago, explains what this means for this patient population ahead of an expected FDA decision in August, 2023.

Relocation led to a reduction in asthma exacerbations, exceeding the effect of inhaled corticosteroids, and was similar to biologic agents.

A healthy 2-year-old boy with atopic dermatitis developed intermittent flares of eczematous patches on his legs with dramatic sparing below the sock line following meals. What is the diagnosis?

This formulation of ibuprofen is the only non-opioid product approved to treat pain in infants that is delivered through injection, according to Cumberland Pharmaceuticals.

Thomas R. Young, MD, discusses how important early screening is in children and adolescents with regard to mental health. He believes a reduction in stigma associated with mental health is occurring and that primary care professionals are encouraging youth to discuss what might be bothering them.

Assessing pain in nonverbal patients remains very difficult, including being able to distinguish it from “behavior” (eg, self-stimulation), says Jon Matthew Farber, MD.

The once-daily topical cream for the treatment of atopic dermatitis (AD) has demonstrated positive topline results in 2 phase 3 studies in adults and children aged 2 years and up. According to Dermavant, a supplemental new drug application (sNDA) filed with the FDA is anticipated in Q1 of 2024.

The REFLECT Scoliosis Correction System from Globus Medical is intended to correct progressive scoliosis in pediatric patients while simultaneously maintaining stability and motion as well as allowing for future modulated growth.

A hybrid closed-loop system can deliver glucose levels in the target range at a higher percentage of time among children aged 2 years to younger than 6 years compared to standard-care, according to a study in the New England Journal of Medicine.

Patients first reported systemic symptoms, such as fevers, headache, and myalgias; vulvar symptoms, which included vulvar pain and dysuria, typically developed 2 days after vaccination and peaked within 5 days.

Our President and CEO, Mike Hennessy Jr, says now is the perfect time to assess your own mental health in honor of Mental Health Awareness Month.

A 9-month-old girl with a history of grunting and poor weight gain for a few months is evaluated in the emergency department for dehydration and respiratory distress. What’s the diagnosis?